Skip to main content
Fig. 3 | BMC Dermatology

Fig. 3

From: Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Fig. 3

Change from baseline in Itch Severity Item score through Week 2. Least squares mean (SE) change from baseline in Itch Severity Item score through Week 2 for patients applying 2 % tofacitinib, 1 % tofacitinib, or vehicle, once daily (a) or twice daily (b). Changes from baseline in ISI were analyzed using a Mixed Model for Repeated Measures without imputation for missing values; QD and BID data were analyzed separately. BID twice daily, ISI Itch Severity Item, LSM least squares mean, PGA-Cm Calculated Physician’s Global Assessment of patients with mild to moderate plaque psoriasis at baseline, QD once daily, SE standard error, tofa tofacitinib

Back to article page